Article source: Medical Rubik's Cube Info
On November 6, Fudan Zhangjiang issued an announcement stating that its Class 1 new drug FZJ-003 capsule is an oral JAK1 selective inhibitor (specification: 25mg, 50mg) for the treatment of moderate to severe atopic dermatitis Phase II clinical trial application Accepted by the Food and Drug Administration
This is the new indication phase II clinical trial of FZJ-003 capsule during the phase I clinical trial for the treatment of rheumatoid arthritis
Atopic dermatitis (AD) is a chronic inflammatory disease, usually in the form of a skin rash
According to past data from WHO, at least 250 million people worldwide are currently suffering from AD, and the incidence of AD patients in China is about 10%
At present, 40% of the affected population are moderate to severe AD patients.
The rash may cover most parts of the body, accompanied by intense and persistent itching, dry skin, cracking, redness or darkening, crusting or oozing, etc.
Itching usually causes sleep disturbances, which can seriously affect the quality of life
At present, biological agents dominate the field of treatment of moderate to severe AD.
Oral JAK preparations have also shown amazing effects in clinical studies, and they have natural advantages in terms of onset time and usage
There is no selective inhibitor of JAK1 on the market in China